Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Receivables (2021 - 2025)

Inmune Bio's Change in Receivables history spans 5 years, with the latest figure at $201000.0 for Q3 2025.

  • For Q3 2025, Change in Receivables rose 138.0% year-over-year to $201000.0; the TTM value through Sep 2025 reached $595000.0, up 108.74%, while the annual FY2024 figure was -$724000.0, 88.31% up from the prior year.
  • Change in Receivables for Q3 2025 was $201000.0 at Inmune Bio, down from $220000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $403000.0 in Q4 2021 and bottomed at -$6.0 million in Q4 2023.
  • The 5-year median for Change in Receivables is $27000.0 (2023), against an average of -$388812.5.
  • The largest YoY upside for Change in Receivables was 420.0% in 2023 against a maximum downside of 2522.58% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $403000.0 in 2021, then crashed by 38.46% to $248000.0 in 2022, then crashed by 2522.58% to -$6.0 million in 2023, then surged by 101.2% to $72000.0 in 2024, then soared by 179.17% to $201000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Change in Receivables are $201000.0 (Q3 2025), $220000.0 (Q2 2025), and $102000.0 (Q1 2025).